<DOC>
	<DOCNO>NCT00095771</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell may effective treatment patient glioma . Drugs arsenic trioxide may also make tumor cell sensitive radiation therapy . Combining arsenic trioxide radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine arsenic trioxide radiation therapy treat patient newly diagnose glioma .</brief_summary>
	<brief_title>Arsenic Trioxide Radiation Therapy Treating Young Patients With Newly Diagnosed Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose arsenic trioxide administer radiotherapy pediatric patient newly diagnose anaplastic astrocytoma , glioblastoma multiforme , gliosarcoma , intrinsic pontine glioma . - Determine toxicity regimen patient . OUTLINE : This dose-escalation study arsenic trioxide ( ATO ) . Patients undergo radiotherapy daily , 5 day week , approximately 6 week . Patients concurrently receive ATO IV 1 hour , 1-5 time weekly , approximately 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ATO maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 3-36 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Clinical neuroradiographic finding consistent intrinsic pontine glioma Histologically confirm anaplastic astrocytoma , glioblastoma multiforme , gliosarcoma Multifocal highgrade glioma allow No exophytic tumor No focal lesion No underlie diagnosis neurofibromatosis No tumor originate anatomic structure adjacent cerebellar peduncle cervical medullary junction PATIENT CHARACTERISTICS : Age 3 21 Performance status Karnofsky 60100 % OR Lansky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Hemoglobin &gt; 10 g/dL Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 2.0 mg/dL Alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) Transaminases &lt; 2.5 time ULN Renal Creatinine &lt; 2.0 time ULN Cardiovascular No seconddegree heart block No absolute QTc interval &gt; 500 msec normal potassium magnesium level Other Not pregnant nursing Negative pregnancy test No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ No serious medical illness Able undergo MRI PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy No prior arsenic trioxide Endocrine therapy Not specify Radiotherapy Not specify Surgery Prior surgery brain tumor allow Other No prior therapy brain tumor More 28 day since prior investigational drug device No concurrent amphotericin B</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
</DOC>